{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:12:37Z","timestamp":1787011957436,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Several studies have suggested that estrogens have a protective function against lymphomagenesis. The treatment of breast cancer is driven by subtype classification, and the assessment of hormone receptor status is important for treatment selection. Thus, we evaluated the association between breast cancer and the incidence of NHL. We conducted a retrospective cohort study using a population-based nationwide registry in South Korea. We selected all women with newly diagnosed breast cancer between January 1st, 2002 and December 31st, 2016 who received curative treatment (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200984,969) and a 1:10 sample of age-matched non-breast cancer controls (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u20091,057,674). Incident breast cancer (time-varying exposure) was the exposure and development of any type of NHL, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mature T\/NK-cell lymphomas, anaplastic large cell lymphoma (ALCL), and unspecified types of NHL, was the outcome. During follow-up, 1564 incident cases of NHL occurred. The fully adjusted Hazard Ratio (HR) for NHL associated with the development of breast cancer was 1.64 (95% CI\u2009=\u20091.34\u20132.00) after adjusting for body mass index, alcohol intake, physical activity, smoking, income, and comorbidity. The adjusted HR for NHL was much higher in participants who were aged\u2009&lt;50\u2009years and who received hormone therapy (either tamoxifen or aromatase inhibitors) than in those \u226550\u2009years or who did not receive hormone therapy, respectively. The development of breast cancer was associated with a significantly increased risk of NHL, particularly follicular lymphoma and mature T\/NK-cell lymphoma. In particular, the risk of NHL was higher in patients receiving hormone therapy and in younger patients.\n                  <\/jats:p>","DOI":"10.1038\/s41408-021-00595-0","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:02:49Z","timestamp":1639440169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study"],"prefix":"10.1038","volume":"11","author":[{"given":"Danbee","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8128-8920","authenticated-orcid":false,"given":"Dongwook","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Soo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Eon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliseo","family":"Guallar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2776-4401","authenticated-orcid":false,"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9081-0266","authenticated-orcid":false,"given":"Juhee","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"595_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"595_CR2","doi-asserted-by":"publisher","first-page":"k3204","DOI":"10.1136\/bmj.k3204","volume":"362","author":"A Bowzyk Al-Naeeb","year":"2018","unstructured":"Bowzyk Al-Naeeb A, Ajithkumar T, Behan S, Hodson DJ. Non-Hodgkin lymphoma. BMJ. 2018;362:k3204.","journal-title":"BMJ"},{"key":"595_CR3","unstructured":"National Cancer Institute. Cancer stat facts: non-Hodgkin lymphoma retrieved. National Cancer Institute; 2021."},{"key":"595_CR4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/jncimonographs\/lgu013","volume":"2014","author":"LM Morton","year":"2014","unstructured":"Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014;2014:130\u201344.","journal-title":"J Natl Cancer Inst Monogr"},{"key":"595_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1470-2045(03)00983-5","volume":"4","author":"L Dal Maso","year":"2003","unstructured":"Dal Maso L, Franceschi S. Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol. 2003;4:110\u20139.","journal-title":"Lancet Oncol"},{"key":"595_CR6","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1182\/blood-2013-07-517292","volume":"123","author":"K Yakimchuk","year":"2014","unstructured":"Yakimchuk K, Hasni MS, Guan J, Chao MP, Sander B, Okret S, et al. Inhibition of lymphoma vascularization and dissemination by estrogen receptor \u03b2 agonists. Blood. 2014;123:2054\u201361.","journal-title":"Blood"},{"key":"595_CR7","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1038\/bjc.2011.484","volume":"105","author":"DM Parkin","year":"2011","unstructured":"Parkin DM. 11. Cancers attributable to infection in the UK in 2010. Br J Cancer. 2011;105:S49\u201356.","journal-title":"Br J Cancer"},{"key":"595_CR8","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1080\/10428194.2021.1872073","volume":"62","author":"A Rajam\u00e4ki","year":"2021","unstructured":"Rajam\u00e4ki A, Sunela K, Prusila REI, Kuusisto MEL, Mercadal S, Selander T, et al. Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24\u2009months. Leuk lymphoma. 2021;62:1639\u201347.","journal-title":"Leuk lymphoma"},{"key":"595_CR9","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1182\/blood-2014-02-554691","volume":"123","author":"K Roemer","year":"2014","unstructured":"Roemer K, Pfreundschuh M. How do estrogens control lymphoma? Blood. 2014;123:1980\u20131.","journal-title":"Blood"},{"key":"595_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4174\/astr.2017.93.6.287","volume":"93","author":"HK Jung","year":"2017","unstructured":"Jung HK, Park S, Kim NW, Lee JE, Kim Z, Han S, et al. Development of second primary cancer in Korean breast cancer survivors. Ann Surg Treat Res. 2017;93:287\u201392.","journal-title":"Ann Surg Treat Res"},{"key":"595_CR11","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.ijrobp.2005.10.022","volume":"64","author":"MJ Hooning","year":"2006","unstructured":"Hooning MJ, Aleman BM, van Rosmalen AJ, Kuenen MA, Klijn JG, van Leeuwen FE, et al. Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. Int J Radiat Oncol, Biol, Phys. 2006;64:1081\u201391.","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"key":"595_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1349-7006.2001.tb01040.x","volume":"92","author":"H Tanaka","year":"2001","unstructured":"Tanaka H, Tsukuma H, Koyama H, Kinoshita Y, Kinoshita N, Oshima A, et al. Second primary cancers following breast cancer in the Japanese female population. Jpn J cancer Res: Gann. 2001;92:1\u20138.","journal-title":"Jpn J cancer Res: Gann"},{"key":"595_CR13","unstructured":"ChangBae, C, SoonYang, K, JunYoung, L & SangYi, L Republic of Korea: health system review. Health Syst Transi. 2009. https:\/\/apps.who.int\/iris\/handle\/10665\/330337."},{"key":"595_CR14","unstructured":"Korea Pharmaceutical Information Service. Korea pharmaceutical information http:\/\/www.kpis.or.kr\/ 2016."},{"key":"595_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jamainternmed.2015.7110","volume":"176","author":"DW Shin","year":"2016","unstructured":"Shin DW, Cho B, Guallar E. Korean National Health Insurance database. JAMA Intern Med. 2016;176:138.","journal-title":"JAMA Intern Med"},{"key":"595_CR16","doi-asserted-by":"publisher","unstructured":"Yang, MS, Park, M, Back, JH, Lee, GH, Shin, JH, Kim, K et al. Validation of cancer diagnosis based on the National Health Insurance Service Database versus the National Cancer Registry database in Korea. Cancer Res Treat. 2021. https:\/\/doi.org\/10.4143\/crt.2021.044.","DOI":"10.4143\/crt.2021.044"},{"key":"595_CR17","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"595_CR18","unstructured":"Kufe DW, Pollock RE, Weichselbaum RR, Robert CB, Ted SG, James FH, Holland-Frei Ccancer medicine. 6th ed. Decker Periodicals Publ Incorporated; 2003."},{"key":"595_CR19","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1182\/blood-2014-02-554691","volume":"123","author":"K Roemer","year":"2014","unstructured":"Roemer K, Pfreundschuh M. How do estrogens control lymphoma? Blood. 2014;123:1980\u20131.","journal-title":"Blood"},{"key":"595_CR20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/annonc\/mds340","volume":"24","author":"EV Kane","year":"2013","unstructured":"Kane EV, Bernstein L, Bracci PM, Cerhan JR, Costas L, Dal Maso L, et al. Postmenopausal hormone therapy and non-Hodgkin lymphoma: a pooled analysis of InterLymph case-control studies. Ann Oncol. 2013;24:433\u201341.","journal-title":"Ann Oncol"},{"key":"595_CR21","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1200\/JCO.2001.19.5.1381","volume":"19","author":"RA Nelson","year":"2001","unstructured":"Nelson RA, Levine AM, Bernstein L. Reproductive factors and risk of intermediate- or high-grade B-Cell non-Hodgkin\u2019s lymphoma in women. J Clin Oncol: Off J Am Soc Clin Oncol. 2001;19:1381\u20137.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"595_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","volume":"16","author":"J Cuzick","year":"2015","unstructured":"Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16:67\u201375.","journal-title":"Lancet Oncol"},{"key":"595_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/humupd\/dmi008","volume":"11","author":"A Bouman","year":"2005","unstructured":"Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update. 2005;11:411\u201323.","journal-title":"Hum Reprod Update"},{"key":"595_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1023\/A:1006489918700","volume":"61","author":"C Rubino","year":"2000","unstructured":"Rubino C, de Vathaire F, Diallo I, Shamsaldin A, L\u00ea MG. Increased risk of second cancers following breast cancer: role of the initial treatment. Breast cancer Res Treat. 2000;61:183\u201395.","journal-title":"Breast cancer Res Treat"},{"key":"595_CR25","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1002\/ijc.21651","volume":"118","author":"L Mellemkjaer","year":"2006","unstructured":"Mellemkjaer L, Friis S, Olsen JH, Sc\u00e9lo G, Hemminki K, Tracey E, et al. Risk of second cancer among women with breast cancer. Int J Cancer. 2006;118:2285\u201392.","journal-title":"Int J Cancer"},{"key":"595_CR26","doi-asserted-by":"publisher","first-page":"e5556","DOI":"10.1097\/MD.0000000000005556","volume":"95","author":"C-Y Lin","year":"2016","unstructured":"Lin C-Y, Chen S-H, Huang C-C, Weng S-F, Lee S-T, Guo H-R, et al. Risk of secondary cancers in women with breast cancer and the influence of radiotherapy: a national cohort study in Taiwan. Med (Baltim). 2016;95:e5556.","journal-title":"Med (Baltim)"},{"key":"595_CR27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10552-005-0338-y","volume":"17","author":"GP Yu","year":"2006","unstructured":"Yu GP, Schantz SP, Neugut AI, Zhang ZF. Incidences and trends of second cancers in female breast cancer patients: a fixed inception cohort-based analysis (United States). Cancer causes Control: CCC. 2006;17:411\u201320.","journal-title":"Cancer causes Control: CCC"},{"key":"595_CR28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10549-007-9509-8","volume":"106","author":"LM Brown","year":"2007","unstructured":"Brown LM, Chen BE, Pfeiffer RM, Schairer C, Hall P, Storm H, et al. Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast cancer Res Treat. 2007;106:439\u201351.","journal-title":"Breast cancer Res Treat"},{"key":"595_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ygyno.2014.10.029","volume":"136","author":"E Molina-Montes","year":"2015","unstructured":"Molina-Montes E, Requena M, S\u00e1nchez-Cantalejo E, Fern\u00e1ndez MF, Arroyo-Morales M, Esp\u00edn J, et al. Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis. Gynecologic Oncol. 2015;136:158\u201371.","journal-title":"Gynecologic Oncol"},{"key":"595_CR30","first-page":"29","volume":"91","author":"J Wilbur","year":"2015","unstructured":"Wilbur J. Surveillance of the adult cancer survivor. Am Fam Physician. 2015;91:29\u201336.","journal-title":"Am Fam Physician"},{"key":"595_CR31","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1158\/1055-9965.EPI-06-0417","volume":"15","author":"DS Alberts","year":"2006","unstructured":"Alberts DS. Second cancers are killing us! Cancer Epidemiol Biomarkers Prev. 2006;15:2019.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"595_CR32","doi-asserted-by":"publisher","first-page":"20718","DOI":"10.18632\/oncotarget.7843","volume":"7","author":"G Talaber","year":"2016","unstructured":"Talaber G, Yakimchuk K, Guan J, Inzunza J, Okret S. Inhibition of estrogen biosynthesis enhances lymphoma growth in mice. Oncotarget. 2016;7:20718\u201327.","journal-title":"Oncotarget"},{"key":"595_CR33","unstructured":"US Food and Drug Administration. Medical device reports of breast implant-associated anaplastic large cell lymphoma. https:\/\/www.fda.gov\/medical-devices\/breast-implants\/medical-device-reports-breast-implant-associated-anaplastic-large-cell-lymphoma 2017. Accessed 20 Aug 2020."},{"key":"595_CR34","first-page":"628","volume":"115","author":"J Kricheldorff","year":"2018","unstructured":"Kricheldorff J, Fallenberg EM, Solbach C, Gerber-Sch\u00e4fer C, Rancs\u00f3 C, Fritschen UV, et al. Breast implant-associated lymphoma. Dtsch Arztebl Int. 2018;115:628\u201335.","journal-title":"Dtsch Arztebl Int"},{"key":"595_CR35","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1245\/s10434-016-5407-9","volume":"23","author":"SA Carter","year":"2016","unstructured":"Carter SA, Lyons GR, Kuerer HM, Bassett RL, Oates S, Thompson A, et al. Operative and oncologic outcomes in 9861 patients with operable breast cancer: single-institution analysis of breast conservation with oncoplastic reconstruction. Ann Surgical Oncol. 2016;23:3190\u20138.","journal-title":"Ann Surgical Oncol"},{"key":"595_CR36","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/annonc\/mdv575","volume":"27","author":"C Laurent","year":"2016","unstructured":"Laurent C, Delas A, Gaulard P, Haioun C, Moreau A, Xerri L, et al. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol: Off J Eur Soc Med Oncol. 2016;27:306\u201314.","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"595_CR37","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/asj\/sjy331","volume":"39","author":"MW Clemens","year":"2019","unstructured":"Clemens MW, Jacobsen ED, Horwitz SM. 2019 NCCN consensus guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Aesthetic Surg J. 2019;39:S3\u2013S13.","journal-title":"Aesthetic Surg J"},{"key":"595_CR38","unstructured":"Curtis, RE. New malignancies among cancer survivors: SEER cancer registries, 1973\u20132000. National Cancer Institute; 2006."},{"key":"595_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4048\/jbc.2020.23.e24","volume":"23","author":"SY Kang","year":"2020","unstructured":"Kang SY, Kim YS, Kim Z, Kim HY, Kim HJ, Park S, et al. Breast cancer statistics in Korea in 2017: data from a breast cancer registry. J breast cancer. 2020;23:115\u201328.","journal-title":"J breast cancer"},{"key":"595_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s12308-019-00369-5","volume":"12","author":"H-R Jung","year":"2019","unstructured":"Jung H-R, Huh J, Ko Y-H, Jeon YK, Yoon SO, Kim SH, et al. Classification of malignant lymphoma subtypes in Korean patients: a report of the 4th nationwide study. J Hematopathology. 2019;12:173\u201381.","journal-title":"J Hematopathology"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00595-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00595-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00595-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:27:29Z","timestamp":1669901249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00595-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":40,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["595"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00595-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,14]]},"assertion":[{"value":"14 December 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"200"}}